Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of altSonflex1-2-3 vaccine 2-dose schedule in African infants
2023-000945-18Phase 2
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of altSonflex1-2-3 in shigellosis, Shigella sonnei infection and Shigella flexneri infection (3 arms), sponsored by GSK. Primary endpoint: Anti-serotype-specific Shigella LPS/OAg serum IgG GMCs/GMTs.
02
Drugs
altSonflex1-2-3
03
Conditions
shigellosisShigella sonnei infectionShigella flexneri infection
Beyond the preview
Go deeper on 2023-000945-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000945-18.